Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Abliva AB (publ) and Cogent Biosciences, as reported by MarketBeat.com.
Get Abliva AB (publ) alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| Cogent Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Cogent Biosciences has a consensus target price of $21.33, indicating a potential upside of 46.02%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Abliva AB (publ).
Profitability
This table compares Abliva AB (publ) and Cogent Biosciences' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| Cogent Biosciences | N/A | -73.27% | -42.95% |
Valuation and Earnings
This table compares Abliva AB (publ) and Cogent Biosciences' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 674.18 | -$14.40 million | ($0.04) | -1.25 |
| Cogent Biosciences | $7.87 million | 85.06 | -$72.27 million | ($2.48) | -5.89 |
Abliva AB (publ) has higher earnings, but lower revenue than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Summary
Cogent Biosciences beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.
About Abliva AB (publ)
(Get Rating)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About Cogent Biosciences
(Get Rating)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.